Tackling Recurring Health Conditions Offers Hope to Patients

By Patricia Miller

Share:

In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Find out more about how Merck (NYSE: MRK), Bio-Techne Corporation (NASDAQ: TECH), Natera (NASDAQ: NTRA) and Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) are revolutionizing healthcare

Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly in the case of cancer or heart conditions. This reality is encouraging more companies to seek treatments for recurring conditions. Here we discuss companies treating recurring health conditions in reference to Merck (NYSE: MRK), Bio-Techne Corporation (NASDAQ: TECH), Natera (NASDAQ: NTRA) and Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL).

Triple-negative breast cancer is the most aggressive type of breast cancer, with the highest risk of recurrence within the first five years after diagnosis. Merck (NYSE: MRK) just had its drug KEYTRUDA® (pembrolizumab) plus chemotherapy approved by the European Commission to treat locally advanced or early-stage triple-negative breast cancer at high risk of recurrence. This offers enormous encouragement to those suffering from this devastating condition.

Meanwhile, Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience announced an agreement to exclusively manufacture Nonagen Bioscience's Oncuria® bladder cancer diagnostic panel using xMAP Luminex® technology. Oncuria is the first-of-its-kind multiplex protein-based urine test to provide early and accurate detection, therapy choice, and disease monitoring of bladder cancer. Sadly, low-grade bladder cancers recur frequently.

Natera (NASDAQ: NTRA) is commercializing a personalized blood-based DNA test to detect and assess how much cancer is left in the body. This will help identify recurrence earlier and help optimize treatment decisions.

And private company Ferring Pharmaceuticals is investigating a live biotherapeutic to reduce recurrent C. difficile infection (CDI) after antibiotic treatment.

Any of these conditions can cause great anxiety to patients, and the potential to treat recurring conditions offers considerable hope of a healthier future. Particularly worrying are the health issues related to the heart. As the heart determines life and death, the shock of a heart condition can bring life to a halt.

Unfortunately, heart problems are not only linked to lifestyle choices but also as a side-effect of many other issues such as infection, autoimmune and inflammatory diseases, cancer, and post-cardiac injury syndromes.

The widespread instance of COVID-19 has led to a rise in heart conditions such as myocarditis and recurrent pericarditis. These are two conditions that Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) is working to treat.

Heart failure continues to persist as a leading cause of death globally, made worse by mounting diabetes, obesity, and high blood pressure cases.

Every year, over 550,000 new cases are diagnosed in the US That's why Cardiol Therapeutics aims to develop treatments to help people live more comfortably with this destructive disease. Their primary focus of interest is in treating acute myocarditis, recurrent pericarditis, and diastolic heart failure.

The company is focused on researching and developing an anti-fibrotic and anti-inflammatory therapy to treat cardiovascular disease (CVD). Its lead product candidate, CardiolRx™, is a pharmaceutically produced oral formulation being clinically designed for cardiovascular medicine use.

RECURRENT PERICARDITIS

Cardiol Therapeutics is delighted to have received a third IND authorization from the US FDA for its flagship formulation CardiolRx™ in CVD. This latest authorization is for a multi-center Phase II open-label pilot study of CardiolRx™ for recurrent pericarditis.

The company’s recurrent pericarditis study will run in parallel with its multi-national Phase II acute myocarditis trial, which is expected to commence imminently.

Dr. Andrew Hamer, Cardiol's Chief Medical Officer, commented:

"With IND authorization now in place, we look forward to ramping up initiation of this important study. We also anticipate benefiting from the clinical trial infrastructure already established for our multi-national acute myocarditis study, which is expected to commence patient enrollment imminently."

Furthermore, this means CardiolRx™ is eligible for orphan drug status in two indications, potentially adding significant value to the company.

Pericarditis refers to inflammation of the pericardium – the membrane, or sac, that surrounds the heart. Symptoms include debilitating chest pain, shortness of breath, and fatigue, which result in physical limitations, reduced quality of life, emergency department visits, and hospitalizations.

Cardiol's recurrent pericarditis study will assess the improvement in objective measures of disease and, during an extension period, evaluate the feasibility of weaning concomitant background therapy, including corticosteroids, while taking CardiolRx™.

The study is expected to enroll 25 patients at major clinical centers specializing in pericarditis in the United States. The study protocol has been designed in collaboration with well-established thought leaders in pericardial disease.

Although generally self-limited and not life-threatening, acute pericarditis is diagnosed in 0.2% of all in-hospital cardiovascular admissions. It is responsible for 5% of emergency room admissions for chest pain in North America and Western Europe.

Recurrent pericarditis is the reappearance of symptoms after a symptom-free period of at least 4–6 weeks following an episode of acute pericarditis. These recurrences appear in 15% to 30% of acute cases and usually within 18 months. Up to 50% of patients with a recurrent episode of pericarditis experience more recurrences.

Cardiol Therapeutics believes there is a significant opportunity to develop a new oral, well-tolerated, and safe therapy for treating recurrent pericarditis to prevent multiple recurrences in the first place.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, declared a quarterly dividend of $0.69 per share for Q3 of 2022. Payment will be made on July 8, 2022, to shareholders of record at the close of business on June 15, 2022. Merck aspires to be the premier research-intensive biopharmaceutical company globally, advancing the prevention and treatment of diseases in people and animals.

Bio-Techne Corporation (NASDAQ: TECH) has extensive immunoassay expertise and world-class manufacturing capabilities. The U.S. FDA granted its drug Oncuria a Breakthrough Device Designation in September 2021, for predicting response to BCG therapy, a first-line treatment for bladder cancer. This provides formal acknowledgment of Oncuria's utility and potential clinical benefit.

Natera (NASDAQ: NTRA) is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is dedicated to oncology, women's health, and organ health. Natera recently announced the appointment of Minetta Liu, M.D., as its new chief medical officer of oncology.

Share:

In this article:

Topics:
Healthcare Services
Healthcare Technology
Industries:
Healthcare
Companies:
Cardiol Therapeutics

IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of One Hundred and Eighty Thousand Dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.


Sign up for VTM Updates

Form submitted successfully!

VTM Exclusive Reports

Crypto Corner

Learn your NFTs from your BTCs